| Symbol | MAZE |
|---|---|
| Name | MAZE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 171 OYSTER POINT BOULEVARD,SUITE 300, SAN FRANCISCO, California, 94080, United States |
| Telephone | 6508505070 |
| Fax | — |
| — | |
| Website | https://www.mazetx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001842295 |
| Description | Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024. Additional info from NASDAQ: |
Coloma Jason V 🔴 sold 1.9K shares of Maze Therapeutics, Inc. (MAZE) at $26.00 Transaction Date: May 15, 2026 | Filing ID: 000004
Read moreBernstein Harold 🟡 adjusted position in 15.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $26.22 Transaction Date: May 14, 2026 | Filing ID: 000021
Read more📋 Coloma Jason V (Officer) plans to sell 35K shares of Maze Therapeutics, Inc. (at $25.95 each, total $895K) Filed: May 15, 2026 | ID: 000561
Read moreNew Form SCHEDULE 13G/A - Maze Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001274173-26-000143 <b>Size:</b> 12 KB
Read moreNew Form EFFECT - Maze Therapeutics, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 9999999995-26-001606 <b>Size:</b> 1 KB
Read more(30% Negative) MAZE THERAPEUTICS, INC. (MAZE) Reports Q2 2026 Financial Results
Read moreMaze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Read moreNew Form POS AM - Maze Therapeutics, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001193125-26-219386 <b>Size:</b> 278 KB
Read moreDandekar Atul 🟡 adjusted position in 0 shares (2 derivative) of Maze Therapeutics, Inc. (MAZE) at $10.42 Transaction Date: May 04, 2026 | Filing ID: 000010
Read moreHOMCY CHARLES J 🔴 sold 7.4K shares of Maze Therapeutics, Inc. (MAZE) Transaction Date: May 04, 2026 | Filing ID: 000002
Read more